Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Tianjin Municipal Science and Technology Committee (23JCYBJC01060)
- Tianjin Municipal Science and Technology Committee (23JCYBJC01050)
- National Natural Science Foundation of China (82000131)
- National Natural Science Foundation of China (82341213)
- CAMS Innovation Fund for Medical Sciences (T-B-105)
- CAMS Innovation Fund for Medical Sciences (2024-I2M-ZH-015)
- CAMS Innovation Fund for Medical Sciences (2024-I2M-TS-023)
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-041)
This publication has 49 references indexed in Scilit:
- Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemic driver mutationsCell Stem Cell, 2025
- In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyCancer Cell, 2024
- Immunotherapeutic targeting of surfaceome heterogeneity in AMLCell Reports, 2024
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13qeJHaem, 2022
- Clonal evolution in leukemiaNature Medicine, 2017
- Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis ofFLT3-ITD to detect patients with prognostically adverse AMLGenes, Chromosomes and Cancer, 2014
- Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesisExperimental Hematology, 2014
- Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLBlood Cancer Journal, 2014
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012